Q1 2025 Theralase Technologies Inc Earnings Call Transcript
Good morning, everyone, and thank you for joining us today. I'm Matthew Perraton, Investor Relations Manager at Theralase Technologies, Inc., and it's a pleasure to welcome our shareholders and stakeholders to our first quarter 2025 Investor Conference Call. We appreciate your ongoing support as Theralase continues to advance through a pivotal phase of transformation.
The second quarter of 2025 will mark a critical inflection point for our company, as after six years of hard work, including the trials and tribulations of running a clinical study through a global pandemic, we will finally complete enrollment in a registrational bladder cancer study. Completion of this milestone will allow us to complete our obligatory 15-month patient follow-up in the third quarter of 2026, which in turn, allows us the opportunity to file a New Drug Application for marketing approval with Health Canada and the FDA for the fourth quarter of 2026.
Assuming we achieve priority review for this new drug and meet all regulatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
